US EditionBreakthrough Male Birth Control Pill Passes Safety Test in Early Clinical Trial
UNITED STATES, JUL 22 – The nonhormonal pill YCT-529 showed no serious side effects in 16 men, marking a key step toward male contraceptive options beyond condoms and vasectomy, researchers said.
- In the first human trial, researchers deemed YCT-529 safe, with no significant side effects, as published Tuesday in Communications Medicine.
- Earlier this year, Gunda Georg, professor in University of Minnesota College of Pharmacy, highlighted that `it will allow a more equitable sharing of responsibility for family planning and provide reproductive autonomy for men,` prompting development of this contraceptive.
- The trial enrolled 16 healthy male volunteers aged 32 to 59, administering single oral doses of 10mg to 180mg, blocking a vitamin A metabolite receptor in the testes.
- Following the phase 1 findings, study authors wrote, that a second trial with 28- and 90-day dosing is planned to study safety and sperm changes.
- Long-Term, this collaboration between University of Minnesota, Columbia University, and YourChoice Therapeutics could revolutionize male birth control options if approved.
18 Articles
18 Articles
Breakthrough male birth control pill passes safety test in early clinical trial
A hormone-free male birth control pill passed its first safety test in ongoing clinical trials, marking a major milestone in its development.The results from the early phase 1 clinical trial testing the safety of the daily pill referred to as YCT-529 were published on Tuesday in the journal Communications Medicine.The pill is designed to decrease sperm count by impairing retinoic acid signaling in the testes, according to its San Francisco-based…
YCT-529 is a big step towards a contraceptive pill for men. Passing its first human test is a good start. This pill will not only give men equal responsibility in family planning, but will also provide relief to women. This can be a revolutionary step for countries like India.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
